Intraperitoneal infection of mice and rats by herpes simplex virus type 2 (HSV-2) but not type 1 (HSV-1) resulted in suppression of antibody formation on subsequent challenge with HSV-1 or HSV-2. Application of silica considerably enhanced antibody formation after primary HSV-1 infection, but only slightly after primary HSV-2 infection. Suppression induced by HSV-2 was, however, reduced significantly by injection of silica 21 days later, on the day of the second injection of HSV-2. Suppression could be detected soon after infection by HSV-2. The degree of this suppression depended on the dose of the injected virus and was abolished by u.v. irradiation of the virus prior to inoculation. Likewise the weak antibody response induced by HSV-2 was abolished for both neutralizing and ELISA antibodies. Infections with HSV-1 evoked considerable numbers of HSV-specific antibodyproducing B cells, when assessed by an enzyme-linked immunospot assay. The B cell response to HSV-2, however, was very weak. Silica considerably enhanced the number of specific antibody-producing B cells only during primary HSV-1 infections. The present results in combination with earlier data demonstrate the central role of macrophages, which seem to be the primary target affected by silica, for enhancement and suppression of HSV-induced antibody generation.
INTRODUCTION
A wealth of work has been performed on the mechanisms and effects of cell-mediated immune reactions against herpes simplex virus (HSV). However, relatively little information exists on the induction of humoral antibody responses against HSV types 1 and 2 (HSV-1 and -2) (Norrild, 1985) . Nonetheless, far-reaching conclusions have been drawn from the observation of elevated antibody levels against HSV-2 in patients with carcinoma of the cervix (Rawls et al., 1968) , and a causal relationship has been assumed between HSV-2 and cancer of the cervix, but this correlation is now being questioned on sero-epidemiological grounds (Vonka et al., 1984a, b) .
Our previous studies on HSV-induced antibody formation covered the genetics and kinetics of this process in mice (Knoblich et al., 1983) . Continuing this work, we have tried to enhance antibody formation by the use of certain drugs. Intraperitoneal (i.p.) application of silica enhanced antibody formation against HSV-1, if given from day 4 before up to day 12 after infection. This observation indicates a long lasting phase of 'suppression' apparently due to the presence of certain functionally active macrophages which can be affected by silica (Knoblich et al., 1983) . Bestatin, a T cell-stimulating dipeptide (Ishizuka et al., 1980) which binds to macrophages and presumably acts via this cell population (Mfiller et al., 1982) , was shown to enhance antibody formation if given from 5 to 8 days after i.p. infection with HSV-1 (Knoblich et al., 1984) .
In experimental HSV-1 infection, application of increasing doses of virus resulted in increased antibody levels. In contrast, HSV-2-infected mice did not produce more than marginal antibody levels even with high virus inocula (Kampe et al., 1985) . This might depend, in part, on the low amounts of antigen in liver, spleen and peritoneal cells (Kampe et al., 1985) . Moreover, 0000-6953 © 1986 SGM our experiments have shown that prior infection with HSV-2, but not with HSV-1, suppresses antibody formation against both HSV-1 and HSV-2 (Kampe et al., 1985) . The aim of the present work was to investigate suppression and enhancement phenomena more thoroughly by testing neutralizing and ELISA antibodies and by using an enzyme-linked immunospot assay to analyse the number of HSV-specific B lymphocytes.
METHODS

Cells and viruses.
Titrations and neutralization tests were done on confluent monolayers of l-or 2-day-old Vero cells as described earlier (Knoblich et al., 1984) . BHK cells served as the source of HSV antigen and control antigen. They were cultured in GMEM with 10~ newborn calf serum. Strains Len (HSV-1), D-316 (HSV-2), HG-52 (HSV-2) and Bry (HSV-2) were used as described earlier (Knoblich et al., 1983; Kampe et aL, 1985) .
Animals. Six-to 8-week-old NMRI outbred mice were purchased from Savo-Ivanovas (Kisslegg, Allg~iu, F.R.G.). BALB/c mice were bred in our own colonies. Rats (3 months old) were of the Wistar strain.
General experimental design. Female mice or rats were infected with various doses of the respective viruses and were re-infected 8 or 21 days later. Twenty-one days after the second injection, mice were bled under CO_, anaesthesia. Female rats were bled by heart puncture repeatedly. Five mice or five rats were used per group. All infections were done i.p. if not otherwise stated.
Neutralization and ELISA tests. These were done and the results were calculated as described earlier (Knoblich et al., 1983 (Knoblich et al., , 1984 . The results are expressed as average values + standard deviations. Statistical evaluation was done by Student's t-test (P < 0.05). Results from representative experiments are presented. Some tests were done with pooled sera from groups of five mice, but in general the sera of each group were tested individually. Crossneutralization tests were performed with some further sera and resulted in titres comparable to those given previously (Kampe et al., 1985) . In essence, after immunization with HSV-1 and testing with HSV-1, higher titres were obtained than when HSV-2 was used. Immunization with HSV-2 resulted in comparable titres if tested with either virus type.
Preparation oJantigen. Antigen-containing culture fluid was harvested 48 h after infection of BHK cells and centrifuged for 20 min (2500 g). The supernatant of uninfected BHK cells was used after repeated freezing and thawing as control antigen. Virus particles in the supernatant were pelleted in a SW27 rotor at 100000 g for 1 h. The pellet was carefully resuspended in phosphate-buffered saline (PBS) and layered onto 15 ml of 30~ sucrose (w/w) in PBS. After a second centrifugation (SW27, 100000 g, 2 h), the pelleted protein was resuspended by sonication in PBS containing 0-1% N P40. In the case of the control antigen the 100000 g pellet was adjusted to the same protein content as the virus antigen.
Enzyme-linked immunospot assay. Measurement of the number of antibody-secreting cells was performed according to the method of Sedgwick & Holt (1983) . In brief, 5 cm Petri dishes were coated with HSV antigen or control antigen overnight at 5 °C, the optimal concentration having been determined by a chequerboard test. In general 50 gg of protein per Petri dish was found to be optimal. The dishes were rinsed twice with PBS to remove unadsorbed material and then unoccupied sites were blocked by incubation with PBS containing 1.5~ bovine serum albumin for 2 h at room temperature.
For the preparation of cell suspensions, spleens of three mice per value (in Fig. 4 and 5) were pooled and passed through a wire mesh. Clumps were allowed to settle at 0 °C for 10 rain. Cells in the supernatant were centrifuged (400 g, 5 rain) and erythrocytes were lysed with 0.83 ~ ammonium chloride. After two washes in Hanks' balanced salt solution, viable cells were counted by the trypan blue method.
Spleen cells were diluted in RPMI 1640 medium and 330 gl of the respective dilutions were added to the dishes. The dishes were incubated for 5 h at 37 °C and then washed three times with PBS and three times with PBS containing 0.05 ~ Tween 20. Incubation with alkaline phosphatase-conjugated goat anti-mouse IgG or IgM serum was carried out for 2 h at 37 °C. Dishes were rinsed again and filled with l ml 5-bromo-4-chloro-3-indolylphosphate (2.3 mM) in agarose (for the method of preparation, see Sedgwick & Holt, 1983) . Blue spots were counted after l h at 37 °C under low power magnification.
Ultraviolet irradiation. This was carried out in a dark room under yellow light. The virus specimens were irradiated at a distance of 8 cm from a Sylvania lamp at 0 °C, with constant mixing on a magnetic stirrer. At various times, specimens were taken and used for the experiments.
Silica treatment. Silica was purchased from Sigma and was suspended and sterilized in Hanks' solution at 150 mg/ml. Each mouse received 0.2 ml of this suspension by i.p. injection. The particle size was 0.5 to 10 gm.
RESULTS
In order to extend our original observation concerning the suppressive effect of HSV-2 on antibody formation against HSV-1 ( Kampe et al., 1985) , we used mice and rats for repeated injections of HSV-1 and -2. In both mice and rats the level of antibodies was much higher if the animals were primed with HSV-1, irrespective of the virus serotype in the subsequent inocula. * Groups of mice were infected i.p. with 1 x 103 p.f.u, of strain Len (HSV-1) and/or HG-52 (HSV-2) and bled 21 days after the last infection. Injections were done at intervals of 21 days. Rats were repeatedly infected with 1 x 104 p.f.u, of strain Len (HSV-1) or HG-52 (HSV-2). They were bled by heart puncture every 21 days and were reinfected the day thereafter. The neutralization and ELISA tests were done with HSV-1 (Len). t 1 and 2 indicate HSV-1 and HSV-2, respectively, in the immunization schedule. :~ Reciprocal values. § NO, Not determined. 215 + 65 ND ND * Groups of mice were infected i.p. at day 0 and treated with 30 mg of silica in Hanks' solution at the indicated times. 1 × 103 p.f.u, of HSV-1 (strain Len), 1 x l03 p.f.u, of HSV-2 (strain D-316) or 1 x l0 s of strain HG-52 (HSV-2) were used for infection. Because of the high mortality, for the latter experiment 12 mice were infected per group, to obtain five mice surviving the infection. Neutralizing antibodies were determined with HSV-1 or HSV-2 as appropriate. The data for HSV-2 antibodies (1 x 103 p.f.u.) were taken from Kampe et al. (1985) .
t Reciprocal values. :~ Significant difference from control group (Student's t-test, P < 0.05).
§ NO, Not determined.
However, a priming dose of HSV-2 depressed antibody formation against secondary infection with HSV-1. These results proved to be true for ELISA and neutralizing antibodies (Table 1) . No elevation of HSV-2-induced antibodies was detectable 42 and 60 days after HSV-2 infection.
In other experiments multiple injections of 1 x 104 p.f.u. HSV-1 or HSV-2 respectively stimulated high antibody levels in rats against HSV-1 but only very low titres against HSV-2 (data not shown). This could also be observed after prolonged times before bleeding.
In previously published dose-response experiments we have shown that HSV-2 is a poor inducer of antibody (Kampe et al., 1985) . Only strain HG-52 stimulates neutralizing antibody formation if injected at a high dose (Kampe et al., 1985) . Moreover, drugs such as bestatin, cyclophosphamide, colchicine, bacterial lipopolysaccharide or dextran sulphate, which are able to enhance antibody formation against HSV-1, proved to be ineffective in elevating antibody levels against HSV-2 ( Kampe et al., 1985) . Table 2 compares the influence of silica on antibody * Groups of five mice were infected or re-infected i.p. with HSV-1 (1 x 103 p.f.u. ;' 1') or HSV-2 (1 x 103 p.f.u. ; '2') at day 0 or day 21. Bleeding was done at day 21 or day 42 after infection. Silica was given at 30 mg/mouse i.p. 4 h after the second infection. The five sera from each group of mice were pooled and used in the ELISA or neutralization tests using HSV-1 (Len) as the ELISA antigen or HSV-1 (Len) and HSV-2 (HG-52) for the neutralization test.
t Reciprocal values. 5 Significant difference of the silica-treated group from the respective control.
formation induced by HSV-1 and HSV-2 in mice. Antibody formation was increased after injection of silica between day -4 and day + 10 after infection with HSV-1, whereas its effect on HSV-2-infected mice (low dose) was small and limited from day -5 up to day + 1 after infection. As might have been expected, a high dose used for infection produced considerable antibody titres; additional injection of silica at different times induced a strong elevation of these titres. Thus, in terms of antibody-generating potency at low doses of infection there exists a fundamental difference between primary infections by HSV-1 and -2 as indicated by the effect of silica. Table 3 shows the influence of silica on antibody titres when given on the day of re-infection after a priming dose of HSV-1 or -2. The increase of antibody titres after i.p. application of silica with the serotype combinations 1-1 or 1-2 was about twofold. However, the antibody titres were enhanced much more by injection of silica with the combination 2-1 and 2-2. It may be concluded that the suppression induced by secondary HSV-2 infection is reduced to a large extent by the injection of silica. Table 4 shows the time course of HSV-2-induced suppression. If HSV-1 was given up to 10 days before HSV-2, a small booster response could be observed. This effect varied as the time decreased between HSV-I injection and injection of HSV-2. If HSV-1 was injected 2 or more days after infection with HSV-2, antibody formation was strongly depressed. This suppression lasted for more than 21 days, if the results from Tables 1 and 2 are also considered. More recent experiments have shown suppression beginning at day 5 by testing of the sera for neutralization. Fig. 1 demonstrates the result of a double infection experiment using HSV-1 with the HSV-2 strain Bry (Kampe et al., 1985) at 102 to 106 p.f.u. Suppression of anti-HSV-1 secondary reactions was not induced by the lowest dose of Bry, but when the dose was increased suppression became evident. Only a very high dose of virus evoked some antibody formation, as was expected from other experiments (not shown) and the results with strain HG-52 (Kampe et al., 1985) . Fig. 2 shows a similar experiment using strain HG-52 (HSV-2) as the priming virus. After infection with 101, 102 or 103 p.f.u, of HG-52, no antibody formation could be detected. However, some antibody formation was induced by higher doses of HG-52 as described previously (Kampe et al., 1985) . In this experiment, even a low dose of strain HG-52 induced a degree of suppression, 102 or 103 p.f.u, generated a strong suppression of antibody formation 8157 + 2280 370 + 142 * Viruses: strain HG-52 (HSV-2, given at day 0) and strain Len (HSV-I, given at day 8) were used i.p. The mice were bled 21 days after the second infection.
t The ELISA tests were performed using BHK cells infected with HSV-1 (strain Len). Reciprocal values. J; The neutralization tests were done with HSV-1 (strain Len). Reciprocal values. § Significant difference from the control (Student's t-test, P < 0.05).
against HSV-1, and inoculation of 104 p.f.u, of HSV-2 followed by 103 p.f.u, of HSV-1 caused a slight booster effect. Thus, the amount of HSV-2 that induced suppression of antibody formation appears to fall within a narrow range. Fig, 3 demonstrates that the suppressive effect of primary HSV-2 infections on antibody formation was not confined to secondary infection by HSV-1 ; it also shows clearly the induction of suppression by a primary infection (10 z or 103 p.f.u.) of strain HG-52 on a secondary high dose (105 p.f.u.) of the same strain. As has been shown previously, the latter dose induced some antibody formation (Kampe et al., 1985) . For comparison, Fig. 3 shows antibody formation induced by a single or a double dose of HSV-1. As can also be seen, footpad infection induced low amounts of antibody, Like i.p. inoculation, this route of introduction produced suppression (data not shown). Table 5 shows the results of an experiment using u.v.-irradiated HSV-2 (strain HG-52) for the We next determined the number of antibody-producing B cells by an enzyme-linked immunospot assay after infection with HSV-1 or HSV-2 with and without application of silica. In these experiments we wanted to see whether HSV-2 indeed induces only low levels of antibody-producing B cells compared to HSV-1 and whether silica was able to enhance strongly the number of antibody-producing B cells after infection with HSV-1, as might be expected considering the results of Table 2 . In contrast, there should be little increase in the number of B cells after infection with HSV-2 and injection of silica. Fig. 4 shows the coincidence of the peaks of the IgM and IgG antibody-producing cells after a primary infection with 3 x 102 p.f.u, of HSV-1. Silica considerably enhanced the number of B cells secreting antibody against HSV-1 ; moreover, the IgM-producing cell peak appeared 1 day before the IgG-producing cell peak. After infection with 2 × 103 p.f.u, of HSV-2, however, few antibody-producing B cells could be found; moreover, the number of spleen cells was not increased. After the application of silica alone, small numbers of antibody-producing B cells could be found (Fig. 5) . When silica was injected after HSV-2, the total number of spleen cells rose to the same extent as after HSV-1 infection. The results of these experiments confirmed our observations on the low antibody-inducing potency of HSV-2 (Kampe et al., 1985) and the data (Table 2) Our experiments have shown that HSV-2 induces suppression of antibody formation not only on secondary infection with HSV-1, but also on secondary infection with the same strain of HSV-2. This phenomenon could be observed both in mice and rats. It seems to be a property common to the several strains of HSV-2 tested (D-316, HG-52, Bry) if used at low doses (102 to 10" p.f.u./mouse). The suppressive effect induced by HSV-2 is detectable early after infection and lasts for at least 21 days after primary infection. The low antibody-inducing potency of HSV-2, therefore, might be due mainly to this suppressive effect of HSV-2 and only to a minor extent to the low amounts of antigen present in the organs, as discussed recently (Kampe et al., 1985) . Because suppression is not induced by HSV-1, we have to consider that a special property of HSV-2 is responsible for the induction of this type of suppression.
In order to explain our observation, we can take into account earlier results from our group. Serum-free supernatants from normal macrophage cultures, if injected into mice, are able to reduce antibody generation against HSV-1 ( Knoblich et al., 1983) . In contrast, the supernatants of macrophages from mice which had been pretreated in vivo with silica or HSV-1 had antibody level enhancing properties. Moreover, silica treatment of mice, before and after HSV-1 infection (day -4 up to day + 10), results in considerable enhancement of antibody formation (Knoblich et al., 1983 ) if compared to HSV-2-infected mice. It is unlikely that in our experiments silica acts by increasing the number of antigen-presenting cells, because typical dendritic cells do not ingest silica; moreover, silica is effective (see above) at a time (5 to 10 days after infection) when antigen is no longer detectable in peritoneal exudate cells (Knoblich et al., 1983) . Silica seems to enhance B cell activity only indirectly by binding lectins (Burger et al., 1983) .
Application of silica destroys macrophages (Allison et al., 1966) . After silica treatment, newly produced cells migrate from the bone marrow into the peritoneal cavity (DuBuy, 1975) , which are destroyed again. Bestatin enhances antibody formation in mice infected with HSV-1 (but not HSV-2), when given between days 5 and 8 post-infection. This compound binds predominantly to macrophages and to a lesser degree to T lymphocytes (M/iller et al., 1982) . Thus, in view of the results mentioned in the foregoing paragraph, it is less likely that silica abolishes 'suppressive' activities of macrophages, but rather it seems to induce an enhancing effect mediated by the release of certain lymphokines (Gery et al., 1981) . The effect of silica on macrophages may also be observed if silica is injected at the day of re-infection. In this case, the HSV-2-induced 'suppression' can be abolished to a large extent, indicating that this phenomenon also depends on macrophages and their regulatory effects on antibody generation.
Thus, macrophages and/or their products seem to be the primary target and control element for regulation of HSV-induced antibody formation, of course in association with the T cell system. N ash et al. (1985) observed a suppression or tolerance of delayed-type hypersensitivity when a high dose (10 s p.f.u.) of HSV-1 was given intravenously. This effect was transferable by lymphocytes. Because our suppression phenomenon is produced by rather low doses only of HSV-2, these effects seem to be different manifestations of the interaction of HSV with the immune system.
Depending on the dose of the infecting virus, the degree of HSV-2-induced suppression may be strong or weak, thus presenting a valuable tool for studying the mechanism of impairment of immune functions by HSV-2. Ultraviolet irradiation of HSV-2 proved to be effective in destroying its suppressive effect on antibody generation. The fact that HSV-2 but not HSV-1 induces suppression indicates very different interactions of these viruses with macrophages.
By analysing the frequency of antibody-producing cells in spleens of HSV-infected mice, results comparable to those seen with serum antibodies were obtained. Silica treatment early after infection increases the number of HSV-specific antibody-producing B lymphocytes after infection with HSV-1. However, no antibody-producing cells could be observed after HSV-2 infections and the effect of silica was slight. Interestingly, the number of spleen cells does not increase after injection of the standard dose of HSV-2, perhaps suggesting that certain factors necessary for an increase of cell number are not being produced. Additional injection of silica, however, results in an increase in the overall number of spleen cells, thus strengthening the view that macrophages are important in the regulation of antibody generation.
The plaque-forming cell assay enables us to study more exactly the regulation and kinetics of HSV-specific antibody-producing B lymphocytes in HSV-1-or HSV-2-infected mice under various experimental conditions. It will be the object of further experiments to investigate the divergent interactions of HSV-1 and HSV-2 with macrophages with regard to antibody formation and the variable influences exerted by macrophages on lymphocyte subsets in vitro and in vivo.
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